RETN rs3745368 polymorphism and resistin level in Javanese ethnic Indonesian obese: a case control study

Main Article Content

Rizki Fajar Utami Pramudji Hastuti Ahmad Hamim Sadewa



Obesity has become a global public health problem. It occurs due to a positive energy balance leading to adipose tissue expansion. White adipose tissue was an endocrine organ which secreted resistin. Resistin also produced by immune cells due to low chronic level inflammation might cause higher resistin level in obese people. Polymorphism +62G>A RETN gene was reported has a relationship with low resistin level and A allele as a protective allele. This study aimed to determine genotype and allele frequency distribution concerning resistin level. Another objective aimed to know the correlation between resistin level with body mass index. The design of the research was a case-control study with 122 people (18-40 y.o.), divided equally in the case group (BMI ≥ 27 kg/m2) and control group (BMI 18.5-24.9 kg/m2) without diabetes mellitus. Blood was taken after fasting a minimal 8 hours. Plasma was used to measure the resistin level. DNA genotyping was analyzed using PCR-RFLP. Genotyping result showed three genotypes of RETN gene +62G>A polymorphism (GG, GA, AA). There was no significant difference in genotype and allele frequency distribution related to obesity status (p=0.680; p=1) and resistin level (p=0.537) between case and control group. There was no significant difference in resistin level between case and control group (p=0.770). Resistin level was correlated with BMI in obese group (p= 0.05; r= -0.25). The present study concludes that there is no significant difference in genotype and allele frequency distribution related to obesity status and resistin level. Resistin level has a negative correlation with BMI.


Download data is not yet available.

Article Details

How to Cite
Utami, R., Hastuti, P., & Sadewa, A. (2019). RETN rs3745368 polymorphism and resistin level in Javanese ethnic Indonesian obese: a case control study. Jurnal Teknologi Laboratorium, 8(1), 41 - 49.
Clinical Chemistry


1. Ellulu M, Abed Y, Rahmat A, Ranneh Y, Ali F. Epidemiology of obesity in developing countries: challenges and prevention. Glob Epidemic Obes. 2014;2(1):2. doi:10.7243/2052-5966-2-2.
2. Penelitian Badan, Kesehatan dan Pengembangan. RISET KESEHATAN DASAR. 2013.
3. Hill JO, Wyatt HR, Peters JC. Energy balance and obesity. Circulation. 2012;126(1):126-132. doi:10.1161/CIRCULATIONAHA.111.087213.
4. Fasshauer M, Blϋher M. Adipokines in health and disease. Trends Pharmacol Sci. 2015;36(7):461-470. doi:10.1016/
5. Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013;4(JUN):1-13. doi:10.3389/fendo.2013.00071.
6. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. 2001:307-312.
7. Degawa-yamauchi M, Bovenkerk JE, Juliar BE, et al. Serum Resistin ( FIZZ3 ) Protein Is Increased in Obese Humans. 2015;88(May):5452-5455. doi:10.1210/jc.2002-021808.
8. Heilbronn LK, Rood J, Janderova L, et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab. 2004;89(4):1844-1848. doi:10.1210/jc.2003-031410.
9. Kusminski CM, Ternan PGMC, Kumar S. Role of resistin in obesity , insulin resistance and Type II diabetes. 2005;256:243-256. doi:10.1042/CS20050078.
10. Menzaghi C, Trischitta V. Genetics of serum resistin: A paradigm of population-specific regulation? Diabetologia. 2010;53(2):226-228. doi:10.1007/s00125-009-1589-z.
11. Park HK, Ahima RS. Resistin in Rodents and Humans. 2013:404-414.
12. Asano H, Izawa H, Nagata K, et al. Plasma resistin concentration determined by common variants in the resistin gene and associated with metabolic traits in an aged Japanese population. Diabetologia. 2010;53(2):234-246. doi:10.1007/s00125-009-1517-2.
13. Capurro AM. Detección de sindrome metabólico en pacientes obesos y su vinculación con resistencia a la insulina , patologías cardiovasculares y diabetes . MP 113289. 2013;28(6):1-23. doi:10.3305/nh.2013.28.6.6912.
14. Tan MS, Chang SY, Chang DM, Tsai JCR, Lee YJ. Association of resistin gene 3'-untranslated region +62G>A polymorphism with type 2 diabetes and hypertension in a Chinese population. J Clin Endocrinol Metab. 2003;88(3):1258-1263. doi:10.1210/jc.2002-021453.
15. Xu JY, Sham PC, Xu A, et al. Resistin gene polymorphisms and progression of glycaemia in southern Chinese: A 5-year prospective study. Clin Endocrinol (Oxf). 2007;66(2):211-217. doi:10.1111/j.1365-2265.2006.02710.x.
16. Boumaiza I, Omezzine A, Rejeb J, et al. Association between four resistin polymorphisms, obesity, and metabolic syndrome parameters in Tunisian volunteers. Genet Test Mol Biomarkers. 2012;16(12):1356-1362. doi:10.1089/gtmb.2012.0156.
17. Gouni-Berthold I, Giannakidou E, Faust M, Kratzsch J, Berthold HK, Krone W. Resistin gene 3’-untranslated region +62G-->A polymorphism is associated with hypertension but not diabetes mellitus type 2 in a German population. J Intern Med. 2005;258(6):518-526. doi:10.1111/j.1365-2796.2005.01566.x.
18. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89(6):2583-2589. doi:10.1210/jc.2004-0535.
19. El-Sayed Moustafa JS, Froguel P. From obesity genetics to the future of personalized obesity therapy. Nat Rev Endocrinol. 2013;9(7):402-413. doi:10.1038/nrendo.2013.57.
20. Menzaghi C, Coco A, Salvemini L, et al. Heritability of Serum Resistin and Its Genetic Correlation with Insulin Resistance-Related Features in Nondiabetic Caucasians. 2015;91(August):2792-2795. doi:10.1210/jc.2005-2715.
21. Boyraz M, Cekmez F, KaraoÄŸlu A, Cinaz P, Durak M, Bideci A. Relationship of adipokines (adiponectin, resistin and RBP4) with metabolic syndrome components in pubertal obese children. Biomark Med. 2013;7(3):423-428. doi:10.2217/bmm.13.14.
22. Gerber M, Boettner a, Seidel B, et al. Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance. J Clin Endocrinol Metab. 2005;90(8):4503-4509. doi:10.1210/jc.2005-0437.
23. De Luis DA, Terroba MC, Cuellar L, et al. Resistin levels in morbid obese patients following the biliopancreatic diversion surgery. Horm Metab Res. 2011;43(3):205-208. doi:10.1055/s-0030-1270529.
24. Koebnick C, Wagner K, Garcia a L, et al. Increase in serum resistin during weight loss in overweight subjects is related to lipid metabolism. Int J Obes (Lond). 2006;30(7):1097-1103. doi:10.1038/sj.ijo.0803242.
25. Savage DB, Sewter CP, Klenk ES, et al. Action in Humans. 2001;50(October):2-5.
26. Alan R. Shuldiner Md, Rongze Yang, M.D., Ph.D. Da-Wei Gong, M.D. Pd. Resistin, Obesity, And Insulin Resistance — The Emerging Role Of The Adipocyte As An Endocrine Organ O. Ethnicity. 2001;13(18):1345-1346.
27. Huang X, Yang Z. Resistin’s, obesity and insulin resistance: the continuing disconnect between rodents and humans. J Endocrinol Invest. 2015. doi:10.1007/s40618-015-0408-2.
28. Schwartz DR, Lazar MA. Human resistin : found in translation from mouse to man. Trends Endocrinol Metab. 2011;22(7):259-265. doi:10.1016/j.tem.2011.03.005.
29. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway. Biochem Biophys Res Commun. 2005;334(4):1092-1101. doi:10.1016/j.bbrc.2005.06.202.